INTRODUCTION AND AIMS:
Diabetic kidney disease is the leading cause of end-stage renal disease worldwide. Despite optimized blood pressure the glomerular filtration rate (GFR) may progressively decline by a median of 3 mL/min/1.73m 2 /year. The aim of this study is to investigate whether changes in glomerular hemodynamics could explain GFR decline in type 2 diabetes (T2D) patients with normal or high normal albuminuria. METHODS: Afferent (Ra), efferent (Re) arteriolar resistance and glomerular hydrostatic pressure (Pglo) were estimated by the Gomez equations in 60 T2D patients. GFR and renal plasma flow (RPF) were measured at baseline by plasmatic clearances of nonradioactive iohexol and ParaAmminoHippurate, respectively. GFR was prospectively monitored every six months up to three years of follow up. Patients with a GFR decline > or < the median cut-off of 3 mL/min/1.73m 2 /year were categorized as "progressors" and "non progressors", respectively. RESULTS: Progressors compared to non-progressors had a higher baseline Ra (3487.361349 
Type 2 diabetic patients (T2D) undergoing dialysis are highly burdened by cardiovascular complications. Oral anti-diabetics agents are either forbidden or at high risk of side effects. Thus improving follow-up by continuous measurement of glycemia should be the main focus to prevent side effect and improve glycemic control and treatment. Vildagliptin (Galvus), can be used in severe and terminal renal impairment and protects against hypoglycemia. Aim of this study was to evaluate the efficacy and safety of vildagliptin (50 mg/d) on top of insulin in hemodialysed T2D, with the help of continuous measurement of glycemia. METHODS: Sixty-five patients treated with multiple daily insulin injections, randomly allocated to different treatment groups (group 1 -G1, n¼33 -usual insulin regimen, group 2 -G2, n¼32 -addition of vildagliptin) in a multicentric, prospective, controlled, open-label, 12 weeks-study. Glucose control was evaluated using Continuous Glucose Monitoring (CGM, I-Pro Medtronic) for 48h, at Week 1 (W1) and Week 12 (W12), HbA1c and daily insulin needs. Statistical analysis was performed in intention to treat . RESULTS: All patients (n¼65) included were treated by hemodialysis. Out of these, 35% received hemodiafiltration) ,dialysate had 1g/l of glucose, 73% had history of diabetic nephropathy, 27% had other nephropathy as main cause of ESRD and type 2 diabetes as comorbidity. Mean duration of dialysis therapy was 4.5 years, and KT/V was 1.38 with no differences in each group. As usually in such population high burden of vascular comobordity was reported with 27% of history of cerebrovascular disease, 31% of cardiac ischemic disease, 17.7% of peripheral vascular arteriopathy, and 50%of diabetic retinopathy Both groups were comparable (G1 vs G2) for age (71.3 6 7.4 vs 69.7 6 9.6 years), BMI (32.1 6 6 vs 34.5 6 6.4 kg/m 2 ), daily doses of insulin (47.7 6 29.2 vs 51.3 6 25.4 IU), HbA1c (7.3 6 1.1 vs 7.3 6 1.1%), and mean glucose at W1 (using CGM, 167.6 6 58.3 vs 149.4 6 76.1 mg/dl). At W12 compared to W1, mean glucose decreased significantly only in G2 (149.4 to 136.9 mg/dl, p <0.05). At W12 in G2 vs G1, time in range (70-180 mg/dl) was greater (77.2 vs 69.5%, p <0.05), time spent > 180 mg/dl was lower (21.27 vs 39.03 %, p <0.05), there was no difference in time spent <70 mg/dl (1.54 vs 1.45%, NS). At W12, HbA1C and insulin requirements were respectively 6.9 6 0.9% vs 7.2 6 1.1% (NS) and 49 6 32 IU/d vs 46 6 23 IU/d (NS). There was no difference in adverse events between both groups. Overall, 8 symptomatic hypoglycemia occurred in G1 and 13 in G2. 
Imarikiren is a novel, potent and selective direct renin inhibitor (DRI) that has high oral availability. Imarikiren is in clinical development for the treatment of patients with diabetic nephropathy. This phase 2 randomized, multicenter, double-blind, placebo-controlled, parallel-group trial was conducted for dosefinding and evaluating the efficacy and safety of Imarikiren in patients with type 2 diabetes mellitus (T2DM) and microalbuminuria. METHODS: We randomized 415 patients with T2DM and microalbuminuria, earlystage nephropathy, to receive once daily Imarikiren 5, 20, 40, 80 mg, placebo or candesartan cilexetil (C.C.) 8 mg. The C.C. reference group which was included to explore the comparative effects of Imarikiren was assessed as an exploratory outcome. The total study duration was 22 weeks including a 8-week pre-treatment period, a 12-week treatment period, and a 2-week follow-up period. The primary endpoint was change in logtransformed urine albumin/creatinine ratio (UACR) from baseline at the end of the 12-week treatment period. This trial is registered with ClinicalTrials.gov and JapicCTI; the registration number is NCT02332824 and JapicCTI-142658. RESULTS: All Imarikiren doses resulted in significantly greater reduction in UACR from baseline at the end of the treatment period compared to placebo (P < 0.0001 for all doses; see Figure) . Clinically meaningful reductions in UACR from baseline in a dose-dependent manner with Imarikiren were demonstrated in this trial. Remission rate to pre-nephropathy stage at the completion of the treatment period, percentage of subjects who have UACR < 30 mg/gCr and whose UACR decreased by 30% from baseline, was observed in 9.0% (6/67 subjects), 9.5% (7/74 subjects), 17.9% (12/67 subjects), and 24.6% (17/69 subjects) of patients treated with Imarikiren 5 mg, 20 mg, 40 mg and 80 mg, respectively compared to 0% (0/66 subjects) with placebo and 14.3% (10/70 subjects) with C.C. 
